Joint Letter Raises Urgent Concerns About Bill 2’s Impact on Access to Arthritis Care

[et_pb_section fb_built="1" _builder_version="4.16" global_colors_info="{}"][et_pb_row _builder_version="4.16" background_size="initial" background_position="top_left" background_repeat="repeat" global_colors_info="{}"][et_pb_column type="4_4" _builder_version="4.16"...

CAPA Submission to the pan-Canadian Pharmaceutical Alliance regarding Expedited Negotiation Pathways

Canadian Arthritis Patient Alliance (CAPA) advocates for a coordinated, inclusive national approach that prioritizes fairness, equity, and meaningful patient involvement at every step. This letter highlights that ENP and TNP only address a narrow part of the broader...

The Patient Room: Chat and Learn for Patient Partners Webinar

On October 15th, 2025, CAPA hosted The Patient Room: Chat and Learn for Patient Partners webinar. Participants were invited to join Therese Lane and Linda Wilhelm for a candid Q&A about lived experience in research and policy—where they started, where they are...

TEAM Project

TEAM Arthritis Information Do you or a loved one have arthritis? Would you like to learn more about it? CAPA—with input from medical experts—has created a comprehensive overview of inflammatory arthritis called TEAM Arthritis Information, which you can view and...

CAPA Shares Patient Feedback on Biosimilar Guidance

On behalf of the Canadian Arthritis Patient Alliance (CAPA), we welcomed the opportunity to provide feedback on the draft guidance for biosimilar biologic drugs. Ensuring that patient perspectives are included in the development of policies is essential to improving...

Advocating for Better Access to Arthritis and Psoriasis Medications in BC

[et_pb_section fb_built="1" _builder_version="4.16" global_colors_info="{}"][et_pb_row _builder_version="4.16" background_size="initial" background_position="top_left" background_repeat="repeat" global_colors_info="{}"][et_pb_column type="4_4" _builder_version="4.16"...